"Mandometer®" Study for Managing Childhood Obesity

Childhood Obesity Clinical Trial

Official title:

Can a Novel Treatment Using "Mandometer®" Technology Improve Weight Loss in a Childhood Obesity Clinic?

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00407420
• Other study ID #: RJ4316
• Status: Completed
• Phase: N/A
• Start date: September 2004
• Est. completion date: January 2013

Study information

• Verified date: September 2019
• Source: University of Bristol
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

We run a successful clinic in Bristol for children with severe obesity who already demonstrate many features to suggest they are at increased risk of early diabetes and heart disease. However, we have found that young children respond better to simple interventions than do adolescents. We have used a new treatment regimen "Mandometer®" to help our most difficult adolescent cases lose weight. We would like to do a study to see if all adolescents might improve weight loss using this technology compared to what we routinely offer

Description:

Childhood obesity is rapidly reaching epidemic proportions in the United Kingdom. Recent studies have indicated a prevalence level for obesity of 15% at 15 years of age. The implications for metabolic, cardiovascular and cancer risk in later life are enormous. The International Obesity Task Force (IOTF) and the European Association for the Study of Obesity (EASO) have identified childhood obesity as a matter for urgent attention. However, there are very few obesity clinics for children in the UK and effective treatment regimens are simply not available. We have developed an obesity clinic at the Royal Hospital for Children in Bristol and observed effective weight reduction in pre-pubertal children. Our simple treatment framework has proved far less effective in adolescence. We have therefore collaborated with an eating disorder clinic from the Karolinska Institute in Sweden to develop a novel therapy to treat obesity using modified equipment originally designed to treat adolescents with DSM-IV eating disorders. Pilot data indicate that adolescents are better able to address the issue of weight reduction within this treatment modality. Having established the software and treatment process we now wish to perform a randomised, control trial to test the efficacy of this new treatment against that currently provided.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 106
• Est. completion date: January 2013
• Est. primary completion date: October 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 10 Years to 18 Years

Eligibility

Inclusion Criteria:

• Obese children and adolescents aged 10-18

Exclusion Criteria:

Children:

• Having associated learning difficulties

• Who have received medication for associated insulin resistance

• Refusal of parent/legal guardian to give informed consent.

Related Conditions & MeSH terms

• Childhood Obesity
• Obesity
• Pediatric Obesity

Intervention

Device:
• Mandometer
A computerised device, Mandometer, providing real time feedback to participants during meals to slow down speed of eating and reduce total intake; standard lifestyle modification therapy.

Behavioral:
• Lifestyle
Typical dietary and activity advice as normally provided in clinic (control).

Locations

Country	Name	City	State
United Kingdom	Bristol Royal Hospital for Children	Bristol

Sponsors (1)

Lead Sponsor	Collaborator
University of Bristol

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Ford AL, Bergh C, Södersten P, Sabin MA, Hollinghurst S, Hunt LP, Shield JP. Treatment of childhood obesity by retraining eating behaviour: randomised controlled trial. BMJ. 2009 Jan 5;340:b5388. doi: 10.1136/bmj.b5388. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	BMI SDS or Z-score	Body Mass Index standard deviation (s.d.) scores also called Z-scores, are measures of relative weight adjusted for a child's age and sex. In terms of this score for weight management, a lower score would be viewed a beneficial outcome at the end of the intervention. The change in BMI SDS was calculated as the value at 12 months minus value at baseline ( a negative score being beneficial).	12 months primary/ 18 months secondary outcome
Secondary	Insulin Sensitivity	Insulin sensitivity was measured by the homeostasis model assessment (HOMA-R) equation: HOMA-R = fasting glucose (mmol/l) × fasting insulin (mIU/l)/22.5. The lower the HOMA-R, the more insulin sensitive the participant is which is considered beneficial to metabolic health.	12 months
Secondary	Speed Food Consumed	Grams of food eaten per minute in Mandometer® arm compared to standard arm at baseline and 12 months. Reducing speed of eating improves satiety and reduces total food consumed at meals in our overall hypothesis.	12 months
Secondary	Percentage Body Fat (Measured Using a Tanita Bio-impedance Monitor Model BC-418MA)	Change in % body fat. Calculated as %body fat at end of intervention minus baseline. A negative value being viewed as beneficial outcome.	12 months